Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2021)

Rani Therapeutics Holdings' (RANI) quarterly Gains from Investment Securities came in at $85000.0 in Q3 2021, up 21.43% quarter-over-quarter from $70000.0 in Q2 2021.

Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2021) Analysis & Trends

Rani Therapeutics Holdings' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $85000.0 for Q3 2021.

  • On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $85000.0 in Q3 2021; TTM through Sep 2022 was $85000.0, a 92.19% decrease from a year earlier, with the FY2021 full-year figure at $371000.0, up 488.89% from the prior year.
  • Gains from Investment Securities improved to $85000.0 in Q3 2021 per RANI's latest filing, from $70000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $718000.0 in Q4 2020 and bottomed at -$672000.0 in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Rani Therapeutics Holdings 144.81 Mn 144.81 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 85,000.00
Sep 30, 2021 85,000.00
Jun 30, 2021 70,000.00
Jun 30, 2021 70,000.00
Mar 31, 2021 216,000.00
Mar 31, 2021 216,000.00
Dec 31, 2020 718,000.00
Dec 31, 2020 718,000.00
Jun 30, 2020 -672,000.00
Jun 30, 2020 -672,000.00